Product Information
IBANDRONATE SODIUM 150 MG TAB is a generic product labeled by Bionpharma Inc., priced at $2.6751 per EA under NDC 69452037874. Its NADAC has been published 156 times since Oct 11, 2023.
FDA first approved this application on Mar 19, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Bionpharma Inc.NDC
69452037874
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBANDRONATE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA078998FDA Approved
3/19/2012
TE Code
AB
On Market Since
5/26/2023
Pharmacological Classes
Price Statistics
The NADAC for IBANDRONATE SODIUM 150 MG TAB has been published 156 times since Oct 11, 2023, and over the history we have for it it has declined 29.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.6751 per EA |
|---|---|
| All-time high | $4.6877 (Dec 13, 2023) |
| All-time low | $2.6751 (Sep 23, 2026) |
| 52-week high | $3.0795 |
| 52-week low | $2.6751 |
| Median price | $3.3363 |
| Average price | $3.4184 |
| Largest weekly change | -37.5% (Nov 20, 2024) |
| Weeks tracked | 156 |
| Tracking since | Oct 11, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bionpharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
IBANDRONATE SODIUM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bisphosphonate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IBANDRONATE SODIUM 150 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for IBANDRONATE SODIUM 150 MG TAB, manufactured by Bionpharma Inc., is $2.6751 per EA (NDC 69452037874), effective Sep 30, 2026.
How has the price of IBANDRONATE SODIUM 150 MG TAB changed over time?
Over the history we have for it, the NADAC for IBANDRONATE SODIUM 150 MG TAB has declined 29.2%. It has been tracked across 156 weekly CMS publications since Oct 11, 2023.
What are the highest and lowest recorded NADAC prices for IBANDRONATE SODIUM 150 MG TAB?
Since Oct 11, 2023, the NADAC for IBANDRONATE SODIUM 150 MG TAB has ranged from a low of $2.6751 (Sep 23, 2026) to a high of $4.6877 (Dec 13, 2023), with a median of $3.3363 per EA.
Are there cheaper alternatives to IBANDRONATE SODIUM 150 MG TAB?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as IBANDRONATE SODIUM 150 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures IBANDRONATE SODIUM 150 MG TAB?
IBANDRONATE SODIUM 150 MG TAB (NDC 69452037874) is labeled by Bionpharma Inc., and CMS classifies it as a generic product.